Latest Infant Formula News

Bubs Australia reports a 14% increase in half-year revenue, powered by a 47% jump in US sales, while other regions face challenges. The company remains optimistic about FDA approval and market recovery in H2 FY26.

Australian Dairy Nutritionals Limited (AHF) is raising approximately $3.47 million through a pro-rata entitlement offer to accelerate its growth plans in China and enhance processing efficiency.

Australian Dairy Nutritionals reported a 152% surge in nutritional powder sales despite regulatory hurdles in Vietnam, while expanding its Future brand footprint across China.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

Clover Corporation delivered a robust FY25 with strong second-half sales and operational milestones, positioning itself for continued growth in FY26 amid ongoing innovation and market expansion.

The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

Australian Dairy Nutritionals reported a 66% year-on-year revenue increase in Q1 FY26, driven by strong nutritional powder sales and expanded distribution in China, while improving cash flow and production capacity.

Clover Corp has reported a standout FY25 with robust revenue and profit growth, driven by new product launches and strategic investments that strengthen its global supply chain and market reach.

Bubs Australia has appointed Paul Jensen as its new Independent Chair and Joe Coote as Managing Director and CEO, signaling a fresh leadership chapter for the infant formula and dairy company.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.